DM
Therapeutic Areas
Telix Pharmaceuticals Limited Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Illuccix® (TLX591-CDx) | Prostate Cancer Imaging (PSMA-positive) | Approved |
| TLX591 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 3 |
| TLX250-CDx | Clear Cell Renal Cell Carcinoma (ccRCC) Imaging | Phase 3 |
| TLX250 | Clear Cell Renal Cell Carcinoma (ccRCC) Therapy | Phase 1 |
| TLX101-CDx | Glioblastoma Imaging | Phase 3 |
| TLX101 | Glioblastoma Therapy | Phase 1 |
| TLX592 | Prostate Cancer (Next-gen Alpha Therapy) | Pre-clinical |
| TLX301 | CD20+ Hematologic Malignancies | Phase 1b |
Leadership Team at Telix Pharmaceuticals Limited
DC
Dr. Christian Behrenbruch
Managing Director and Group Chief Executive Officer
MD
Mr. David C. (Dave) Marek
Chief Commercial Officer
DK
Dr. Kevin (Kevan) Richardson
Chief Operating Officer
MR
Mr. Richard G. Vale
Chief Financial Officer
DD
Dr. David (Dave) N. Cade
Chief Medical Officer
DM
Dr. Michael (Mick) J. McCahon
Chief Scientific Officer
MG
Ms. Gillian M. Wright
General Counsel and Company Secretary
DA
Dr. Andreas (Andi) Klug
Senior Vice President, Head of Europe
MR
Mr. Ryuichi (Roy) Mizuno
Senior Vice President, Head of Japan & Asia Pacific
MA
Mr. Andrew (Andy) M. Killingsworth
Non-Executive Chairman